$FATE

FATE THERAPEUTICS INC

CIK:0001434316|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration revenue	$ 2,082	$ 1,907	$ 3,381	$ 3,536
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 24,387	$ 27,430	$ 49,090	$ 56,566
General and administrative	8,829	11,445	18,425	25,218
Total operating expenses	33,216	38,875	67,515	81,784
Loss from operations	(31,134)	(36,968)	(64,134)	(78,248)
Other income (expense):
Interest income	1,555	2,921	3,422	6,257
Change in fair value of stock price appreciation milestones	(580)	(73)	(660)	207
Other income	0	50	0	93
Total other income	975	2,898	2,762	6,557
Net loss	(30,159)	(34,070)	(61,372)	(71,691)
Other comprehensive loss:
Unrealized loss on available-for-sale securities, net	(40)	(129)	(233)	(206)
Comprehensive loss	$ (30,199)	$ (34,199)	$ (61,605)	$ (71,897)
Net loss per common share, basic	$ (0.25)	$ (0.29)	$ (0.51)	$ (0.61)
Net loss per common share, diluted	$ (0.25)	$ (0.29)	$ (0.51)	$ (0.61)
Weighted-average common shares used to compute basic net loss per share	120,397,390	118,528,046	120,215,028	118,452,214
Weighted-average common shares used to compute diluted net loss per share	120,397,390	118,528,046	120,215,028	118,452,214

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net loss	$ (61,372)	$ (71,691)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,698	6,611
Stock-based compensation	7,447	14,535
Accretion and amortization of premiums and discounts on investments, net	(1,536)	(1,915)
Deferred revenue	(382)	(393)
Change in fair value of stock price appreciation milestones	660	(207)
Loss on disposal of property and equipment	0	(36)
Changes in operating assets and liabilities:
Accounts receivable	213	2,144
Prepaid expenses and other assets	653	3,139
Accounts payable and accrued expenses	(4,518)	(9,342)
Right-of-use assets and lease liabilities, net	(1,119)	(1,241)
Net cash used in operating activities	(54,256)	(58,396)
Investing activities
Proceeds from sale of property and equipment	0	122
Purchases of property and equipment	(319)	(2,558)
Purchases of investments	(87,075)	(99,437)
Maturities of investments	125,538	164,137
Net cash provided by investing activities	38,144	62,264
Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs	412	0
Proceeds from FT819 CIRM award	1,324	0
Proceeds from FT836 CIRM award	0	(1,325)
Net cash provided by financing activities	1,736	1,325
Net change in cash, cash equivalents and restricted cash	(14,376)	5,193
Cash, cash equivalents and restricted cash at beginning of the period	56,855	46,283
Cash, cash equivalents and restricted cash at end of the period	42,479	51,476
Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment in accounts payable	$ 0	$ 993

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 32,429	$ 46,628
Accounts receivable	703	916
Short-term investments	121,341	157,029
Prepaid expenses and other current assets	3,480	4,131
Total current assets	157,953	208,704
Long-term investments	0	1,472
Property and equipment, net	51,546	56,925
Operating lease right-of-use assets	40,554	41,609
Restricted cash	10,050	10,227
Total assets	260,103	318,937
Current liabilities:
Accounts payable	3,258	2,656
Accrued expenses	14,904	20,024
CIRM award liability, current portion	9,508	8,448
Deferred revenue	0	381
Operating lease liabilities, current portion	4,922	4,562
Total current liabilities	32,592	36,071
CIRM award liability, net of current portion	2,377	2,112
Operating lease liabilities, net of current portion	70,753	73,287
Stock price appreciation milestones	943	283
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at June 30, 2026 and December 31, 2025	3	3
Common stock, $0.001 par value; authorized shares-350,000,000; issued and outstanding-116,694,106 at June 30, 2026 and 115,359,735 at December 31,2025	117	115
Additional paid-in capital	1,749,116	1,741,259
Accumulated other comprehensive income (loss)	(117)	116
Accumulated deficit	(1,595,681)	(1,534,309)
Total stockholders’ equity	153,438	207,184
Total liabilities and stockholders’ equity	$ 260,103	$ 318,937